News Releases

News Releases

Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Dec 07, 2021
Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1 results and rationale around SSc-ILD as new PRA023 indication to be presented in conference call

Prometheus Biosciences to Present at Upcoming Investor Conferences

Nov 02, 2021
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of

Prometheus Biosciences to Host Virtual R&D Day for Investors on July 28, 2021

Jul 15, 2021
Featuring management and expert-led discussions on the science of TL1A, including the application and clinical trial approach of PRA023 in Inflammatory Bowel Disease SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company
Displaying 11 - 20 of 36